The primary role of the Hdm2/Mdm2 oncoprotein is to regulate the levels and activity of the transcription factor p53. Hdm2 synthesis is itself tightly controlled and, as demonstrated by a recently described SNP (SNP309) in the hdm2-P2 promoter, minor variations in Hdm2 expression have phenotypic consequences on radiation sensitivity and cancer predisposition. To further define mechanisms regulating Hdm2 expression, we have investigated the effects of the GC-selective DNA-binding drug, Mithramycin A (MA) on hdm2 mRNA transcription, trafficking, and translation. Firstly we show that the constitutive hdm2-P1 promoter is inhibited by MA. We define, for the first time, the minimal sequence elements that are required for P1-promoter activity and identify those which confer MA sensitivity. Secondly, MA induces p53-dependent transcription from the hdm2-P2 promoter. Thirdly, and critically, MA also inhibits Hdm2 synthesis at the post-transcriptional level, with negative effects on hdm2 mRNA nuclear export and translation. This study highlights the complex interplay between the pathways that regulate Hdm2 protein synthesis in cancer cells, and furthermore emphasizes the export of hdm2 mRNA from the nucleus to the cytoplasm as a key point of control in this process.
Introduction
The oncoprotein Hdm2 (Mdm2 in mouse) is the primary negative regulator of the activity of the transcription factor p53 in proliferating cells (Momand et al., 2000; Vogelstein et al., 2000) . Hdm2 regulates p53 function through multiple mechanisms, including concealing its activation domain from the transcriptional machinery (Oliner et al., 1993) , and targeting it for ubiquitination, nuclear export and proteosomal degradation (Michael and Oren, 2003) . In the absence of functional Hdm2/ Mdm2, cells in the early embryo undergo spontaneous p53-dependent apoptosis (Jones et al., 1995; Montes de Oca Luna et al., 1995) , normal human fibroblasts in culture undergo cell-cycle arrest (Blaydes and WynfordThomas, 1998) , and the in vivo proliferation of tumour cells which retain a wild-type p53 gene is inhibited (Vassilev et al., 2004) . However, the sensitivity of the p53-Hdm2 regulatory module is such that even small changes in the levels of Hdm2/Mdm2 can have profound effects on cellular biology. Most notably, the transgenic manipulation of mice to incorporate a hypomorphic allele of mdm2 that results in as little as a 20% reduction in Mdm2 protein levels, renders the animals markedly more sensitive to ionizing radiation (Mendrysa et al., 2003) . In humans, a single nucleotide polymorphism (SNP309) in the hdm2 gene which results in increased Hdm2 expression has been shown to correlate with accelerated rates of tumorigenesis in a subset of individuals (Bond et al., 2004 .
Regulation of the levels and activity of Hdm2 therefore has the potential to play a major role in the control of proliferation and survival of both normal and cancer cells. It is already clear that regulation of Hdm2 activity at the post-translational level is critically important for the control of its function, with Hdm2 phosphorylation and protein:protein interactions being a critical point of convergence for both stress-and survival-induced signalling pathways (Meek and Knippschild, 2003; Michael and Oren, 2003) . Of particular note is the stress-induced increase in Hdm2 protein turnover that contributes to the activation of p53 following DNA damage (Stommel and Wahl, 2004) , the phosphorylation of Hdm2 by Akt kinase, which promotes the accumulation of Hdm2 in the nucleus and is an important component of the effects of pro-survival factors such as Insulin-like Growth Factor-1 (Shaulian et al., 1997; Mayo and Donner, 2001; Ashcroft et al., 2002; Feng et al., 2004) , and the induction of the Hdm2 antagonist, p14
ARF by oncogenic stress (Stott et al., 1998; Sherr and Weber, 2000) .
Perhaps less thoroughly investigated are the mechanisms whereby the rates of Hdm2 protein synthesis are regulated. However it is clear, not least from the numerous studies in which elevated levels of hdm2 mRNA and protein expression have been shown to occur in human tumours (Onel and Cordon-Cardo, 2004) , that this is an equally important point of control. Transcription of hdm2 mRNA encoding the full length p53-binding form of Hdm2 (p90) occurs from two promoters P1 and P2. The mRNA transcript generated from the P1-promoter is translated approximately 10-fold less efficiently than the P2 transcript owing to the presence of two upstream open reading frames (uORFs) in the first exon (Brown et al., 1999; Jin et al., 2003) . The P1-promoter is thought to be responsible for the low level, basal expression of Hdm2/Mdm2 in unstressed cells (Mendrysa et al., 2003) , though its activity has recently been found to be regulatable in response to Akt kinase signalling in some cells (Chang et al., 2004) . Transcription from the P2-promoter is highly induced by p53 owing to the presence of two p53-binding sites o100 bp 5 0 to the transcriptional start site (Zauberman et al., 1995) . This response to p53 is the key in regulating the duration of the p53-response to genotoxic stress (Lev Bar-Or et al., 2000) . A number of other signalling pathways and transcription factors also impinge upon the activity of the p53-Hdm2 module via the regulation of the activity of the P2-promoter, including thyroid hormone receptors (Qi et al., 1999) , HEY1 and HES1 transcriptional repressors (Huang et al., 2004) , MYCN (Slack et al., 2005) and Ras-Raf-MEK-ERK signalling (Ries et al., 2000; Phelps et al., 2003 Phelps et al., , 2005 . Hdm2 protein synthesis is also subject to post-transcriptional control; the export of hdm2 message from the nucleus to the cytoplasm is controlled by cellular MEK activity (Phelps et al., 2005) , and hdm2 mRNA translation rates are elevated in some cancer cells (Landers et al., 1997; Trotta et al., 2003) .
There remain, however, many examples in the literature where distinct growth-or stress-induced signalling pathways have been shown to regulate the levels of expression of Hdm2, and as a consequence cellular p53 activity, through non-defined and potentially novel mechanisms. In the recent paper describing the SNP309 in the hdm2-P2 promoter (Bond et al., 2004) , the authors made use of the GC-selective DNAbinding anti-tumour antibiotic, Mithramycin A (MA), to show increased activity of the P2-promoter in cells homozygous for the SNP309 (G/G) was dependent on Sp1 transcription factors that bind GC-rich sequences. Given that MA is a genotoxic compound that is able to strongly activate the DNA-binding activity of p53 (Koutsodontis and Kardassis, 2004) , we were intrigued by Bond et al's data that MA did not noticeably induce p53-dependent Hdm2 expression in cell lines with an intact p53-responsive pathway, irrespective of their SNP309 status. In this paper we have further investigated the mechanistic basis for the effects of MA on Hdm2 synthesis. We demonstrate that MA does strongly induce transcription from the p53-dependent hdm2-P2 promoter; however, it also inhibits transcription from the constitutive hdm2-P1 promoter, which we show is critically dependent on a GC-rich element for its activity. Mithramycin A also reduces the export of both hdm2 mRNA transcripts from the nucleus to the cytoplasm further inhibiting Hdm2 protein synthesis.
Results
Mithramycin A inhibits Hdm2 protein synthesis in T47D breast cancer cells The study by Bond et al. (2004) demonstrated that MA decreased levels of SMP14 antibody-reactive Hdm2 protein in a number of cell lines that were G/G homozygous for SNP309. We therefore initially used one of these lines, breast cancer-derived T47D cells, to confirm the dose response ( Figure 1a ) and time course (Figure 1b ) of the effects of MA on Hdm2 protein synthesis. For these studies we used antibody 2A9, which unlike several antibodies that recognize Hdm2 including SMP14 (Zhang and Prives, 2001) , is not known to be affected by post-translational modification of Hdm2. Consistent with the previous study, MA at concentrations above 100 nM reduced Hdm2 levels after 24 h exposure, with the maximum effect being observed Figure 1 Mithramycin A blocks Hdm2 protein synthesis. (a) T47D cells were cultured in the presence of the indicated concentration of MA for 24 h before Hdm2 protein levels were determined by Western blotting using 2A9 antibody. As internal control, the same membrane was re-probed with an antibody to b-actin. (b) T47D cells were cultured in the presence of 200 nM MA for the indicated time before Hdm2 protein levels were determined by Western blotting using 2A9 antibody. A second Hdm2 antibody, 2A10, gave similar results (data not shown). (c) T47D cells were cultured in 5 mg/ml Actinomycin D for the indicated time before RNA was extracted and semi-quantitative PCR used to determine relative levels of hdm2-P1, hdm2-P2, c-myc and b-actin transcripts. (d) T47D cells were cultured with DMSO carrier or 200 nM MA for 24 h before 50 mM MG132 was added to the medium to block proteasome-mediated degradation of Hdm2. Cells were cultured for a further 0-60 min before Hdm2 protein levels were determined by Western blotting. (Phelps et al., 2005) . The half-life of mdm2 mRNA has also been reported to be relatively short in some cells (Hsing et al., 2000) . This appeared to be incompatible with the proposed mechanism of inhibition of Hdm2 synthesis by MA in these cells, that is, direct binding of the hdm2-P2 promoter to inhibit transcription (Bond et al., 2004) , as this would be expected to result in a rapid decrease in Hdm2 protein levels. We therefore examined the turnover of hdm2 mRNA following blockade of mRNA synthesis by Actinomycin D (Figure 1c) . Compared with the labile c-myc mRNA, which dropped to a level below the limits of detection within 3 h of exposure to Actinomycin D, hdm2 mRNA was relatively stable in T47D cells, with both hdm2-P1 and -P2 transcripts having half-lives of >7 h. This could, therefore, account for a delayed decrease in Hdm2 protein levels in response to MA, even if the drug does rapidly inhibit hdm2 mRNA synthesis. Finally, we tested whether MA does, in fact, inhibit Hdm2 protein synthesis, rather than promoting its proteosomal-mediated degradation (Figure 1d ). Hdm2 has a half-life of approximately 15 min in proliferating cells, and rapidly accumulates to high levels following the inhibition of its degradation by the proteosome inhibitor MG132 (Phelps et al., 2005) . In cells in which Hdm2 protein synthesis is blocked, MG132 does not cause Hdm2 accumulation (Phelps et al., 2005) , whereas decreasing Hdm2 protein levels by promoting its degradation is reversed by MG132 (Phillips et al., 2006) . MG132 does not lead to an accumulation of Hdm2 in MA-treated T47D cells (Figure 1d ), providing strong evidence that MA inhibits Hdm2 protein synthesis.
Mithramycin A downregulates expression of mRNA from the 'constitutive' Hdm2-P1 promoter, but not the 'inducible' P2-promoter Having confirmed that MA had the expected effects on Hdm2 protein synthesis in T47D cells, we then examined its effects in a cell line that retains a functional stressinduced, p53-dependent transcriptional response. MCF-7 breast cancer cells exposed to MA for 24 h showed a strong induction of p53 protein by MA (Figure 2a ). This was accompanied by a large increase in the levels of mRNA from the p53-inducible hdm2-P2 promoter (750% (Po0.05), Figure 2b ). Despite this induction, Hdm2 protein levels were reduced in MA-treated MCF-7 cells (Figure 2a ), albeit not to as great an extent as in T47D cells.
While it is the regulation of the P2-promoter that is normally responsible for the induction of Hdm2 expression in response to stress-induced p53 activation, the mRNA from the P1-transcript is actually more abundant than the P2 transcript in many cell types, including unstressed MCF-7 cells (Phelps et al., 2003) . Mithramycin A caused a reduction in hdm2-P1 transcript levels to approximately 35% of control levels in MCF-7 cells (Po0.05, Figure 2b ), and hence the net effect of MA on levels of hdm2 coding sequence containing transcripts was a decrease ( Figure 2b ). As it is likely that this downregulation of P1-transcript levels contributes to the overall effects of MA on Hdm2 protein levels, we next sought to establish the mechanistic basis underlying this observation.
Sequence elements required for hdm2-P1 promoter activity We first confirmed that the effect of MA on hdm2-P1 transcript levels was seen in cell lines other than MCF-7 ( Figure 3a ). Mithramycin A significantly reduced P1-transcript levels in both T47D and MDA-MB231 breast cancer cell lines (reductions of 74.8% (Po0.05) and 33.1% (Po0.05), respectively). The basis for the difference between the cell lines in the magnitude of this response remains to be determined. Additionally, while both these cell lines express functionally inactive mutant p53 and hence MA did not cause the same striking increase in P2-transcripts as in MCF-7, the drug did still induce a modest increase in the P2-transcript levels in both cell lines (206% (Po0.05) and 272% (Po0.05), respectively). The effect of MA on the total levels of coding hdm2 mRNA was a reduction of comparable magnitude to the decrease in P1-transcript levels (data not shown), reflecting our previous observation (Phelps et al., 2003) that P1 is the predominant transcript in both cell lines.
The hdm2-P1 promoter has not been previously subjected to functional analysis. Therefore, to investigate the regulation of hdm2-P1 observed in all cell lines examined, we amplified a 1057 bp region of the hdm2-P1 promoter from normal human genomic DNA, and cloned it into the pGL3Basic luciferase reporter vector, to produce the vector hdm2P1luc01. This region 
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included 61 bp of sequence 3 0 to the expected transcriptional start site (Oliner et al., 1992) including an ATG from one of the two uORFs in exon 1 which inhibit translation of the hdm2-P1 message (Brown et al., 1999) . In order to confirm that transcription was initiating, as would be expected, from 5 0 to this ATG, as well as to The human genomic DNA sequence present in the minimally active vector, Hdm2luc05DATG, was aligned with the murine mdm2 P1-promoter region, using ClustalW (Thompson et al., 1994) . Highlighting of conserved regions was performed using BOXSHADE. The suspected major transcriptional start site in hdm2 is shown with a black arrow, other potential start sites identified as ESTs are shown as grey arrows. uORF indicates the position of the ATG that we have mutated. The 5 0 -end of the different reporter vectors used is indicated. Matinspector (http://www.genomatix.de/) was used to identify potential transcription factor binding sites (Core fit>0.95, Matrix fit>0.925) in the human sequence. Boxed annotations are positions of potential transcription factor binding sites, or GC-rich regions I-V, that we have modified by site-directed mutagenesis in certain vectors. 
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A Phillips et al improve translation of the luciferase reporter gene, this ATG codon was mutated (DATG vectors) . This resulted in an approximately threefold enhancement in reporter activity in all cell lines tested (data not shown), so all subsequent experiments were performed using reporter vectors with this mutation. We then made progressive 5 0 -deletions of the inserted genomic sequence to identify the minimal region of the promoter that was required for constitutive activity (Figure 3b) . In MDA-MB231 cells, the plasmid hdm2P1luc05DATG, which contains only 221 bp of genomic DNA sequence, had comparable activity to the original 1057 bp containing vector. Deletion of a further 120 bp of 5 0 -sequence (hdm2 P1luc06DATG) resulted in loss of >90% of the promoter activity.
To facilitate further dissection of this promoter region we performed an alignment analysis of this 221 bp region of the human P1-promoter with the comparable region of the murine promoter (Figure 3c ). It has previously been observed that the 5 0 -UTR region encoded by exon 1 is relatively poorly conserved between species (Zauberman et al., 1995) and therefore we reasoned that any conserved elements between the species in the promoter regions may well be functionally important. The human sequence was also analysed for potential transcription factor binding sites. The first observation was that there is no TATA box element to provide a specific transcriptional start site, and BLAST analysis of both human and mouse EST databases identified sequences with different 5 0 -ends in both species, which is suggestive of multiple start sites. Based on this analysis, a further set of deletion mutants was then generated, and transfected into MDA-MB231 and MCF-7 cells (Figure 3d ). The activity of hdm2P1luc05-DATG in each cell line was set as 100%, and the other vectors compared to this. In MCF-7 cells, as in MDA-MB231 cells, hdm2P1luc01DATG and hdm2P1luc05-DATG vectors have approximately equal activity, and therefore the minimal active region is similar in both cell lines. A deletion of 50 bp from the 5 0 -end of hdm2P1luc05DATG to produce hdm2P1luc09DATG did not result in loss of activity in MDA-MB231 cells, and actually resulted in significantly (Po0.01) increased activity in MCF-7 cells. A further deletion of the 18 bp sequence between À110 and À92 resulted in a reduction to 21.4 and 12.5% of hdm2luc05DATG activity in MCF-7 and MDA-MB231 cells, respectively. This region contains a CCAAT box consensus sequence. Deletion of 39 bp from the 3 0 -end of hdm2P1luc05-DATG resulted in a significant (Po0.01) reduction in activity to 45.3% in MDA-MB231. In MCF-7 cells, whether or not this deletion had a significant effect was dependent on the absence or presence of the 50 bp between À160 and À110 at the 5 0 -end of the inserted sequence.
Having established the minimal region required for P1-promoter activity, we then set out to establish the mechanism whereby MA inhibits expression of the P1-transcript. Mithramycin A is thought to inhibit transcription by binding GC-rich regions in promoters, and preventing them from recruiting activating transcription factors, such as Sp1. This suggests that there are one or more GC-rich regions in the P1-promoter that are necessary for its activity, the effects of which can be abrogated by MA binding. We therefore made and analysed a series of hdm2P1luc09DATG-based vectors containing small mutations in GC-rich motifs in the promoter. One of these mutations (GCII) resulted in a >85% loss of promoter activity in both cell lines (Figure 4a ). Three other mutations (GCIII, GCIV, GCV) resulted in smaller, though significant (Po0.05), reductions in activity in MCF-7 cells. In MDA-MB231 cells only one of these other mutants, GCIV, had a significant effect (P ¼ 0.001), though, interestingly the GCIV mutation resulted in a >twofold increase in reporter activity in these cells, compared to a 42.8% decrease in MCF-7.
The GCII region that is necessary, though not sufficient, for >85% of promoter activity in both cell lines is also well conserved between the human and mouse promoters. We therefore generated further mutants to characterize this region, and individually disrupted a potential ETS family binding site (defined here as site ETSb), and a consensus binding site for the ubiquitously expressed ZF5F factors, which overlaps with the 5 0 part of the GCII region. The effects of all these mutants of the GCII regions were examined in MDA-MB231, MCF-7 and T47D cells (Figure 4b) . A 2 bp substitution that destroyed the ETSb site resulted in significant (all Po0.01) 71.7, 83.0 and 88.0% reductions in promoter activity in MDA-MB231, MCF-7 and T47D cells, respectively. The 6 bp substitution to destroy the ZF5F site also reduced promoter activity by 61.6% (Po0.001) in MDA-MB231, 70.8% (Po0.001) in MCF-7, and 65.5% (Po0.01) in T47D cells. In all cell lines, the effect of the GCII mutation was slightly greater than either the ETSb or ZF5F mutations, suggesting there may be more than one functional transcription factor binding sites in this region, which the GCII mutant is more effective at inactivating. To investigate whether the GCII region could be the functionally relevant target for MA in the hdm2-P1 promoter, we exposed cells transfected with various reporter vectors to MA (Figure 4c ). Mithramycin A significantly inhibits activity of hdm2P1luc09DATG to 19.8% (Po0.01) of control levels; this inhibition is not seen with the GCII mutated vector. This is consistent with the GCII region being the functionally relevant binding site on the promoter for MA, though the low levels of baseline promoter activity when the GCII site is mutated does mean that a small inhibitory effect of MA on the promoter activity could have been difficult to detect. As MA is generally regarded as an inhibitor of Sp1 transcription factor activity, we attempted to determine the role of Sp1 in transcription from the P1-promoter. However, these experiments proved inconclusive as, while B90% knockdown of Sp1 protein was achieved, we did not observe any decrease in endogenous hdm2-P1 message levels, nor was a known Sp1-responsive reporter vector affected by the Sp1 siRNA. Potentially, other members of the Sp transcription factor family may be compensating for the loss of Sp1 in these experiments.
Finally, because the hdm2-P1 transcript is poorly translated, it is not clear to what extent it may contribute to the overall levels of Hdm2 protein in unstressed cells. MCF-7 cells were transfected with siRNAs targeting the unique 5 0 -UTR in the hdm2-P1 transcript, and the effects compared to an siRNA targeting the Hdm2 coding sequence. (Figure 4d ). Compared to a control siRNA, Hdm2-CDS siRNA reduced Hdm2 protein expression by approximately 85%, and hdm2-P1 siRNA caused a 30% reduction. This confirms that, despite the fact that the hdm2-P1 transcript is poorly translated compared to the P2-mRNA, transcription from the P1-promoter does contribute to the levels if Hdm2 protein in these cells, and therefore MA is likely to exert its effects on Hdm2 protein levels by, at least in part, inhibiting transcription from this promoter.
Regulation of the nuclear export of hdm2 mRNA by MA The above results do not, however, satisfactorily explain why the large induction in hdm2-P2 transcripts in MCF-7 cells treated with MA does not result in elevated Hdm2 protein levels in these cells. Previous studies in our laboratory have indicated the importance of mRNA trafficking and translation as a regulatable point of control of Hdm2 protein synthesis (Phelps et al., 2005) . We therefore set out to investigate whether MA affects Hdm2 synthesis at the post-transcriptional level. Cells were incubated with MA or DMSO carrier control and then subjected to hypotonic lysis and homogenization to obtain 
A Phillips et al nuclear and cytoplasmic extracts. The fractionation was verified by comparison of semi-quantitative PCR detection of the small nuclear RNA snRNA U6, which is enriched in the nuclear compartment, compared to gapdh mRNA which is present in both nucleus and cytoplasm. Part of the cytoplasmic extract was then subjected to separation through 30% sucrose buffer to isolate polyribosome-bound mRNA. In MCF-7 cells (Figure 5a ) MA again caused a large induction of P2-transcript when total cellular RNA was analysed (1530%). However, when cytoplasmic mRNA was analysed, the hdm2-P2 transcript was under represented relative to gapdh mRNA, compared to the total RNA analysis. Following MA, levels of cytoplasmic P2-transcript did increase, but the relative increase was only 620%. In contrast, there was a 2560% increase in the levels of P2-transcript in the nucleus. This provides strong evidence that MA treatment leads to the preferential retention of hdm2-P2 transcripts in the nucleus. Furthermore, when the association of P2-transcripts with polyribosomes was analysed, the increase following MA treatment was only 213%. In support of these observations, MA caused a reduction in levels of total hdm2-P1 transcripts in the cells, as before (43%), whereas the reduction in cytoplasmic P1-mRNA was again greater (83%), indicating that the nuclear export of this transcript is similarly inhibited. The reduction in polyribosome-associated P1-transcript was nearly 90%. As the siRNA analysis shows the P1-transcript, which is known to be poorly translated, contributes to only a relatively small proportion of the total levels of Hdm2 protein. Overall therefore, in MCF-7 cells treated with MA, the combination of large decrease in polyribosome-associated P1-transcript with the small net increase in translated P2 transcript, results in the modest decrease in Hdm2 protein levels as shown in Figure 2a . Figure 5b shows that this effect of MA is not restricted to MCF-7 cells, as in MA-treated T47D cells both P1-and P2-transcripts show an accumulation in the nuclear compartment, and up to 50% under-representation in the cytoplasmic RNA, compared to RNA extracted from whole cells. The subcellular distribution of mRNA encoding p21 WAF1 and bax were not affected by MA in these assays (data not shown), demonstrating that this effect of MA has selectivity for hdm2 mRNA. In T47D cells, there was a reduction in both P1-and P2-transcripts in the polyribosome fraction following MA treatment, consistent with the greater effect of the drug on Hdm2 protein synthesis in these cells. Finally, the effects of MA on the nuclear export of hdm2 mRNA in T47D cells are similar to the consequences of inhibiting MEK kinase activity that we reported previously (Phelps et al., 2005) . We therefore examined whether inhibition of MEK kinase activity occurred following 24 h exposure of T47D cells to MA (Figure 5c ). Mithramycin A did not affect phosphorylation of ERK1/2 by MEK, demonstrating that MA acts independently of MEK to inhibit hdm2 mRNA nuclear export.
Discussion
Both the basal and inducible levels of expression of Hdm2 protein are critical in determining the phenotypic response to cellular stress (Lev Bar-Or et al., 2000; Vogelstein et al., 2000; Mendrysa et al., 2003; Ma et al., 2005) . An inherited polymorphism in hdm2, can result in variations in radiation responsiveness, and tumour susceptibility between individuals within a population (Bond et al., 2004; Harris et al., 2005) , tissue-specific 
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pathways which elevate Hdm2 expression may affect the selection pressure for the acquisition of p53 mutations in different types of cancer (Wynford-Thomas and Phelps et al., 2003) , tumour-associated genetic aberrations that increase Hdm2 protein levels can promote cancer progression (Oliner et al., 1992; Momand et al., 1998; Onel and Cordon-Cardo, 2004) , and the differential effects of genotoxic chemotherapeutics on the expression of Hdm2 may contribute to their ability to induce p53-dependent cell-death pathways (Arriola et al., 1999; Inoue et al., 2001) . Therefore, it is critically important to understand the mechanistic basis for the regulation of Hdm2 expression. Mithramycin A is an anti-tumour antibiotic which inhibits transcription from promoters containing GC-rich DNA sequences (Miller et al., 1987; Blume et al., 1991) . Mithramycin A is licensed for clinical use, and therefore the elucidation of its mechanisms of action is of interest in that respect (Remsing et al., 2003; Ferrante et al., 2004) . In this report, however, we have focussed on its application as a useful tool to probe the mechanisms whereby the expression of Hdm2 is regulated in cancer cells.
Mithramycin A is a potent inducer of sequencespecific DNA-binding competent p53 (Koutsodontis and Kardassis, 2004) . The p53 target genes WAF-1 and PUMA are not, however, induced by MA. This is because p53-dependent transcription of these genes requires cooperation between p53 and Sp1 transcription factors. Mithramycin A, by interacting with GC-rich DNA, prevents Sp1 from binding to the WAF-1 and PUMA promoters (Blume et al., 1991; Koutsodontis and Kardassis, 2004) . The hdm2-P2 promoter contains two adjacent p53-responsive elements in close proximity to the transcription start site, and is highly sensitive to activation by p53 (Zauberman et al., 1995) . Here we have shown that MA strongly induces expression of the hdm2-P2 transcript in wild-type p53 expressing cells, and therefore hdm2-P2 promoter activation by p53 is not Sp1 dependent. This differential dependence on Sp1 for p53-dependent transcription between hdm2 and certain other p53-responsive genes may potentially play a role in defining the amplitude and longevity of p53 activation following distinct stimuli in different cell types.
The hdm2-P2 promoter is also regulated by factors other than p53, the extent of this p53-independent transcription again being an important regulator of cellular p53 activity (Ries et al., 2000) . T47D breast cancer cells, despite expressing functionally inactive mutant p53, express similar levels of the hdm2-P2 transcript to wild-type p53 expressing MCF-7 cells (Phelps et al., 2003) . We have previously shown that the activity of a hdm2-P2 promoter reporter construct in these cells is partially dependent on a highly GC-rich repetitive sequence, which is a likely binding site for MA. Subsequently, Bond et al, 2004 , showed that T47D cells were homozygous (G/G) for the SNP309 in the P2-promoter region. They provided compelling evidence that SNP309 acts to extend an Sp1 site, resulting in increased, Sp1-dependent, activation of this promoter. To support this interpretation, they showed that MA strongly downregulates Hdm2 protein expression in T47D cells, and proposed that this was due to an inhibition of Sp1-dependent P2-promoter activity by MA in these cells. Here we show that MA actually causes a modest increase in the levels of P2 transcript in T47D cells. It is important to note, however, that this does not exclude a role for these GC-rich sequences in the basal activity of the promoter in these cells, as MA may also prevent transcriptional repressors from binding to the promoter, potentially overriding any effects on activation by Sp1, to result in a net upregulation of activity. Clearly, however, the downregulation of Hdm2 protein expression by MA in these T47D cells in not due to the inhibition of transcription from the P2-promoter.
We did however, discover, at least two distinct mechanisms whereby MA does inhibit the synthesis of Hdm2 protein; inhibition of transcription from the constitutive P1-promoter, and inhibition of the nuclear export of both P1-and P2-hdm2 mRNA transcripts. Both of these effects occurred in MCF-7 and T47D cells lines, the less-striking reduction in Hdm2 levels in MCF-7 being accounted for by the MA-induced upregulation of p53-dependent P2-promoter activity in these cells. Mechanisms regulating transcription from the hdm2-P1 promoter have, to date received little attention. This is primarily because the promoter has not, until recently (Chang et al., 2004) , been show to be regulatable, and also because the transcript is poorly translated (Brown et al., 1999; Jin et al., 2003) . However, murine models have shown that Mdm2 protein synthesis is dependent almost exclusively on the P1-transcript in many unstressed normal tissues in vivo (Mendrysa et al., 2003) , as well as in tumour cells in which the mdm2 gene is amplified (Barak et al., 1994) . Using siRNA directed towards the unique 5 0 -UTR in the P1-transcript, we show here that that transcript does contribute modestly to the levels of Hdm2 protein in the MCF-7 breast cancer cell line, though the precise extent of this contribution cannot be determined as the siRNA does not deplete 100% of the P1-transcript.
We have defined a 171 bp minimal region of the P1-promoter that is required for its constitutive activity. Further deletions and mutations identified two regions, loss of either of which results in >80% reduction in promoter activity. These are the 18 bp sequence between À110 and À92, which contains an evolutionarily conserved CCAAT box, and a GC-rich region, which we have defined as GCII, which is also highly conserved between human and murine promoters. The residual activity of a reporter vector in which this GCII element is mutated is insensitive to MA, indicating that this is the key binding site for MA that is responsible for inhibition of P1-promoter activity by the drug. Further analysis of the promoter revealed that while the above two regions were essential for promoter activity in all three cells lines examined, mutation of other sequences had differential effects between cell lines. These included the 50 bp region between À160 and À110, removal of which had no effect in MDA-MB231 cells, but approximately doubled the activity in MCF-7 cells, and the highly conserved GCIV region immediately 5 0 to the transcriptional start sites, deletion of which either enhanced or reduced activity depending on the cell line examined. These results demonstrate that, while this promoter may be ubiquitously expressed, it is likely to be regulated by different sets of transcription factors depending on the cell type. Potentially this may account for our findings (data not shown) that whereas P1 promoter activity in murine fibroblasts is dependent on an active Aktsignalling pathway (Chang et al., 2004) , the >90% reduction of Hdm2 protein levels that results from 48 h inhibition of Akt activity in MCF-7 cells is not associated with any decrease in hdm2-P1 transcripts. Further work will be required to determine the extent to which regulation of transcription from the P1 promoter contributes to the elevated levels of Hdm2 protein expression in human cancers (Onel and Cordon-Cardo, 2004) .
We have demonstrated recently that the export of hdm2 mRNA is rate-limiting for the synthesis if Hdm2 protein, and dependent upon the activity of MEKdependent signalling pathways (Phelps et al., 2005) . We show now that MA treatment also reduces the cytoplasmic to nuclear ratio of hdm2 mRNA and that this effect contributes to the reduced rates of Hdm2 protein synthesis in MA-treated cells. Of particular note was our finding that, although MA-induced p53 activation and a strong upregulation of hdm2-P2 transcript levels in MCF-7 cells, these transcripts accumulated to a greater extent in the nucleus, rather than being exported to the cytoplasm. As a consequence of this, and potentially additional effects of MA on hdm2 mRNA translation, levels of hdm2-P2 transcripts being actively translated in polyribosome complexes increased only Btwofold following MA treatment. This effect of MA, combined with its inhibition of P1-promoter activity, prevents the MA-from upregulating Hdm2 protein levels. This is likely to result in the upregulation of p53 in response to MA being enhanced, and prolonged, compared to DNA-damaging agents that do not inhibit Hdm2 expression.
The majority of cellular mRNAs, in the form of ribonucleoprotein complexes, utilize common pathways for their export from the nucleus to cytoplasm (Erkmann and Kutay, 2004) . More recently, however, it has become clear that a subset of cellular mRNAs utilize more selective processes for their export, through the interaction of RNA sequences, often in their 3 0 -UTR, with RNA sequence-or structure-selective binding proteins that direct the export of these mRNAs (Keene, 2003) . The translation initiation factor eIF4E for example has, in addition to its well-described role in the cytoplasm, a nuclear role in the regulation of export of a subset of mRNAs including cyclin D1 (Culjkovic et al., 2005) . This function may be involved in the oncogenic function of eIF4E, and both this (Kentsis et al., 2004) , and possibly other (O'Shea et al., 2004) , selective mRNA export pathways are potential targets for cancer therapy. The proteins involved in the selective export of hdm2 mRNA remain to be identified, however our finding that hdm2 mRNA export is not only dependent upon MEK kinase activity, but is also sensitive to the anti-tumour antibiotic MA in a MEKindependent manner, not only highlight the importance of regulated mRNA export in controlling Hdm2 synthesis, but should also prove useful in the elucidation of its mechanism.
Materials and methods
Cell culture T47D, MDA-MB231 and MCF-7 breast cancer cell lines were cultured in Dulbecco's modified Eagle's medium (Invitrogen Ltd, Paisley, UK) supplemented with 10% fetal calf serum (Autogen Bioclear, Calne, UK) as described previously (Phelps et al., 2003) . The following reagents were dissolved in dimethyl sulphoxide (DMSO) at the indicated concentration before adding to the medium where stated; 200 mM Mithramycin A (Sigma Aldrich Co., Poole, UK), 10 mM MG132 (Sigma). Actinomycin D (Sigma) was dissolved in ethanol at a concentration of 5 mg/ml.
Protein analysis
Cells were washed with phosphate-buffered saline, pelleted by centrifugation at 1000 Â g, snap frozen and stored at À701C. Western blotting was performed as described previously (Phelps et al., 2005) , and membranes were probed for Hdm2 (monoclonal antibody 2A9 (Chen et al., 1993) ), p53 (DO-1, Serotec), phospho-Thr-202/Tyr-204 ERK 1 and ERK2 (E10), total ERK1 and ERK2 (both from Cell Signaling Technology, Beverly, MA, USA). Equal protein loading was confirmed on all immunoblots using rabbit anti b-actin antibody (Sigma, Aldrich CO., Prole, UK). Bands were visualized by chemiluminescence (Supersignal, Pierce) using a Fluor-S MAX system (Bio-Rad).
RNA analysis RNA extraction from cell pellets was performed using either RNABee (Biogenesis Inc.) or RNeasy (Qiagen, Crawley, UK). Semi-quantitative RT-PCR analysis was performed as described previously (Phelps et al., 2003) , using oligo dT (Promega Ltd, Southampton, UK) for the reverse transcriptase reaction. Primers for amplification of c-myc were c-mycU 5 0 -CCATCGATTTCTTCCTCATCTTC-3 0 and c-mycD 5 0 -TGAGGAGACACCGCCCAC-3 0 . Taqman quantitative polymerase chain reaction (qPCR) analysis of hdm2 transcripts was performed as described previously (Phelps et al., 2005) .
Plasmids
A 1057 bp region of the hdm2-P1 promoter (À997 to þ 61 relative to the major transcriptional start site) was amplified from normal human genomic DNA and ligated into pGL3ba-sic using the MluI/XhoI sites (Promega). Mutation of the ATG codon present in this sequence ( þ 57 to þ 59) to TTG was introduced using a single base change in the reverse primer to generate hdm2P1luc01DATG. Additional constructs containing deletions of the hdm2-P1 promoter (luc03-luc10) were generated by proof-reading PCR of hdm2P1luc01DATG using primers containing MluI and XhoI sites, followed by ligation into pGL3basic. Analysis of potential transcription factor binding sites was performed using MatInspector (www.geno matix.de/cgi-bin/matinspector/matinspector.pl). Further mutations were introduced using site-directed mutagenesis and all constructs were verified by sequencing (MWG Biotech, Ebersberg, Germany). Forward site-directed mutagenesis primers used are as follows, the position of the mutation being underlined (complementary reverse primers not shown): DGCI 5 0 -TTGGCGGAAGCGTCTAGACGGTTGTGTGCG-3 0 ; Transfections Cells were transfected with reporter vectors using Lipofectamine 2000 reagent (Invitrogen), and reporter assays were preformed using a Dual-Glot luciferase assay (Promega) on cells transfected in 96-well plates, with normalization to Renilla luciferase expressed from pRLSV40 (Promega). The normalized data is presented as relative luciferase units (RLU). For transfection of siRNA, cells in six-well plates were transfected with 100 pmol of either control (non-silencing) siRNA or siRNA targeting different hdm2 transcripts: the coding sequence of hdm2 was targeted using validated siRNA from Qiagen (Hs_mdm2; will target both P1 and P2 transcripts); hdm2-P1 siRNA was targeted to the following sequence in exon 1, 5 0 -AAGATGGAGCAAGAAGCCGAG-3 0 (will target hdm2-P1 transcript only). Cells were harvested and analysed 72 h after transfection.
Cellular fractionation
Cellular fractionation before RNA extraction or polyribosome analysis was performed using hypotonic lysis. Cells were washed twice with serum-free medium containing 10 mg/ml cycloheximide, then scraped and pelleted by centrifugation at 365 Â g. Pellets were resuspended in hypotonic lysis buffer (10 mM Tris-HCl pH 7.6, 1 mM potassium acetate, 1.5 mM magnesium acetate, 2 mM dithiothreitol, 1 unit/ml RNAse inhibitor) and lysed on ice using a Dounce homogenizer.
Lysates were centrifuged at 12 000 Â g to separate the cytoplasmic extract from the nuclear pellet. For polyribosome analysis, aliquots of the cytoplasmic lysates were layered over a cushion of 30% sucrose in hypotonic lysis buffer and centrifuged at 130 000 Â g for 2.5 h at 41C. The supernatant was removed and the remaining polyribosome-bound RNA pellet was used for RNA extraction.
